These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32028327)

  • 21. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of antiretroviral therapy with brain aging changes among HIV-infected adults.
    Soontornniyomkij V; Umlauf A; Soontornniyomkij B; Gouaux B; Ellis RJ; Levine AJ; Moore DJ; Letendre SL
    AIDS; 2018 Sep; 32(14):2005-2015. PubMed ID: 29912063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Limiting cardiovascular events associated with HIV and antiretroviral therapy.
    Brenner BG; Baril JG
    AIDS; 2017 Nov; 31(18):2551-2553. PubMed ID: 29120901
    [No Abstract]   [Full Text] [Related]  

  • 24. Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy.
    Israel S; Elinav H; Elazary R; Porat D; Gibori R; Dahan A; Azran C; Horwitz E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database.
    Ruzicka DJ; Imai K; Takahashi K; Naito T
    BMJ Open; 2018 Jun; 8(6):e019985. PubMed ID: 29903786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
    Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
    [No Abstract]   [Full Text] [Related]  

  • 27. [Interactions of cardiac and antiretroviral medication].
    Egger S; Drewe J
    Herz; 2005 Sep; 30(6):493-503. PubMed ID: 16170680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly.
    Stader F; Courlet P; Kinvig H; Penny MA; Decosterd LA; Battegay M; Siccardi M; Marzolini C
    Clin Pharmacol Ther; 2021 Feb; 109(2):471-484. PubMed ID: 32772364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
    Ciccullo A; Baldin G; Cossu MV; Passerini M; Borghetti A; Capetti A; Di Giambenedetto S
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):4-5. PubMed ID: 31476877
    [No Abstract]   [Full Text] [Related]  

  • 31. Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.
    Stader F; Kinvig H; Battegay M; Khoo S; Owen A; Siccardi M; Marzolini C
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.
    Veil R; Poizot-Martin I; Reynes J; Goujard C; Seng R; Delobel P; Cotte L; Duvivier C; Rey D; Tran L; Surgers L; Allavena C; Lascoux Combe C; Cheret A; Meyer L
    AIDS; 2020 Mar; 34(4):493-500. PubMed ID: 31764069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study.
    Spinner CD; Kümmerle T; Krznaric I; Degen O; Schwerdtfeger C; Zink A; Wolf E; Klinker HHF; Boesecke C
    J Antimicrob Chemother; 2017 Sep; 72(9):2679-2681. PubMed ID: 28859438
    [No Abstract]   [Full Text] [Related]  

  • 35. Cheaper HIV treatment for children.
    Burki T
    Lancet; 2020 Dec; 396(10266):1873. PubMed ID: 33308458
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
    Ryom L; Lundgren JD; El-Sadr W; Reiss P; Kirk O; Law M; Phillips A; Weber R; Fontas E; d' Arminio Monforte A; De Wit S; Dabis F; Hatleberg CI; Sabin C; Mocroft A;
    Lancet HIV; 2018 Jun; 5(6):e291-e300. PubMed ID: 29731407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development.
    Smith JM; Flexner C
    AIDS; 2017 Jun; 31 Suppl 2():S173-S184. PubMed ID: 28471948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy.
    Olin JL; Klibanov O; Chan A; Spooner LM
    Ann Pharmacother; 2019 Aug; 53(8):812-832. PubMed ID: 30770025
    [No Abstract]   [Full Text] [Related]  

  • 39. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
    Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
    AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort.
    Chan P; Goh O; Kroon E; Colby D; Sacdalan C; Pinyakorn S; Prueksakaew P; Reiss P; Ananworanich J; Valcour V; Spudich S; Paul R;
    AIDS Res Ther; 2020 Jan; 17(1):1. PubMed ID: 31907064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.